LBO — MAIMONIDES MEDICAL CENTER
IRR: 35.0% | MOIC: 4.48x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
35.0%
IRR
4.48x
MOIC
$247.2M
Entry EV
$689.9M
Exit EV
$127.2M
Equity Invested
Sources & Uses
S&UTotal · $247.2M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $96.0M | 38.8% | |
| Sub Debt | $24.0M | 9.7% | |
| Equity | $127.2M | 51.5% | |
| Enterprise Value | $240.0M | 97.1% | |
| Transaction Fees | $7.2M | 2.9% | |
| Total Uses | $247.2M | 100.0% |
Interpretation
INTAt 4.48x MOIC and 35.0% IRR over 5 years, this deal exceeds the typical 20% hurdle — strong candidate.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $65.7M |
| Exit Ev | $689.9M |
| Net Debt At Exit | $120.0M |
| Equity At Exit | $569.9M |
| Equity Invested | $127.2M |
| Total Value Created | $442.7M |
| Value From Growth | $437.9M |
| Value From Multiple | $12.0M |
| Value From Deleveraging | 0.0% |